Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.57 |
| ▸ | PDE1A | P54750 | 11/20 | 0.57 |
| ▸ | PDE1B | Q01064 | 11/20 | 0.57 |
| ▸ | PDE1C | Q14123 | 11/20 | 0.57 |
| ▸ | PDE5A | O76074 | 4/20 | 0.57 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104838 | 0.88 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL4246621 | 0.83 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5116939 | 0.80 | PDE7A (0.72) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL4246900 | 0.79 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL2680154 | 0.75 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3952083 | 0.75 | PDE7A (0.50) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5102984 | 0.74 | PDE7A (0.73) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL291618 | 0.73 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5103345 | 0.73 | PDE7A (0.51) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL20694154 | 0.72 | PDE7A (0.78) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429598-B2 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-06-03 | — | — | US | disclosed |
| EP-1400244-A1 | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | Warner-Lambert Company LLC (US) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | PDE3A, PDE5A, PDE3B | PDE7A 21/4885PDE4D 12/4885PDE1A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.